$HZNP - $IMMU - $IOVA - On our trading list. All with news today or analyst comments & our opinions. Horizon price target raised on good Tepezza drug news. IMMU has positive comments from Piper Sandler. Iovance still favorable at Piper, keeps Overweight rating.Trade Idea: Sell IOVA $30 puts.Horizon Therapeutics price target raised to $60 from $50 at StifelStifel analyst Annabel Samimy raised the firm's price target on Horizon Therapeutics to $60 from $50 and keeps a Buy rating on the shares. After speaking to Dr. Bobby Korn, oculoplastic surgeon at UCSD Shiley Eye Institute, the analyst says it was "impressive" to hear that Horizon's Tepezza has changed his treatment approach and will now be used first-line, ahead of any surgery. Thus far, Tepezza was working in all patients placed on therapy, and the doctor surmised that the drug was working beyond the immunological response and changing the biology of disease, Samimy tells investors in a research note. With a population upwards of 100,000 according to Korn, the analyst sees Tepezza's opportunity exceeding $1B in peak sales and the $200,000 expected in 2020. Samimy sees upside in Horizon Therapeutics shares.Our Take: HZNP is a good biotech growth name to hold on to. $HZNP, Horizon Therapeutics Public Limited Company / H1 Immunomedics' sacituzumab activity remains consistent, says Piper SandlerPiper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $40 price target on Immunomedics after the company presented initial data from two sacituzumab cohorts in bladder and endometrial cancer. The analyst said that "most notable" is the bladder data from Cohort 2 of TROPHY-U-01 in post-CPI platinum-ineligible disease which showed a 29% overall response rate in 21 patients, identical to the 29% ORR observed so far in the post-chemo/CPI Cohort 1. Catanzaro believes that if this response rate is maintained over a bigger cohort it should be supportive of an accelerated sBLA submission in this setting.\Piper says Iovance data for lifileucel continue to 'mature favorably' - maintains Overweight rating.Piper Sandler analyst Joseph Catanzaro said data from cohort 2 of lifileucel's melanoma study are continuing to "mature favorably" and he sees "no real surprises with this update." The analyst, who still thinks the durability of responses will make lifileucel "a very meaningful option" for post-PD-1 melanoma patients, believes that lifileucel's data package is fully supportive of approval in this setting. Catanzaro keeps an Overweight rating on Iovance Biotherapeutics shares.Our Take: The recent drop in IOVA due to a secondary offering may provide a good buying opportunity and trading opportunities. Under $30 would be a nice price to get in. Possibly sell some $30 strike puts.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try..